reports
Nordic American Tankers Ltd (NYSE: NAT) – Important transactions in a ...
Nordic American Tankers Ltd (NYSE: NAT) – Important transactions in a strong market. Solid prospects Friday, January 16, 2026 Dear Shareholders and Investors, I am pleased to inform you that the following transactions have been carried through: The earlier announced preliminary agreements for the construction of two suezmax tankers have now been signed.The price is $86 million for each ship.The South Korean shipyard Daehan Shipbuilding is the builder. The ships will be delivered to NAT in 2028.This week we have also finalized the previously announced sale of two vessels built 2004 and...
Jeffs’ Brands: KeepZone AI Enters into a Distribution Agreement with A...
Jeffs’ Brands: KeepZone AI Enters into a Distribution Agreement with Advanced Vehicle and Threat Detection Systems Developer Tel Aviv, Israel, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace expanding into the global homeland security sector through advanced artificial intelligence (“AI”)-driven solutions, today announced that its wholly-owned subsidiary, KeepZone AI Inc. (“KeepZone”), has entered into a non-exclusive distribution agreement (the “Agreement”) w...
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, ...
Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue Research-use-only offerings are commercially available, enabling immediate product and service revenue generation Targets the global CRO market of $47.9 billion in 2025 and growing at 7% CAGR BERKELEY, Calif, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces the launch ...
Hillman Sets Fourth Quarter 2025 Earnings Release and Results Presenta...
Hillman Sets Fourth Quarter 2025 Earnings Release and Results Presentation Date CINCINNATI, Jan. 16, 2026 (GLOBE NEWSWIRE) -- () (“Hillman”), a leading provider of hardware-related products and merchandising solutions, plans to host a conference call to discuss its results for the thirteen and fifty-two weeks ended December 27, 2025 on Tuesday, February 17, 2026 at 8:30 a.m. Eastern Time. Hillman will issue its earnings release and 2026 guidance on the same day prior to the results presentation. President and Chief Executive Officer Jon Michael Adinolfi and Chief Financial Officer Roc...
- Hiroyuki Terada
- Joel Scheiman
- Julie Boote
- Lindsay Whipp
- Pelham Smithers
- Thao Nguyen
- William Nestuk
The PSA Research Round-Up for Week to 16 January 2026
Weekly Comment Summary The benchmark of an auto-stock-trading-as-a-tech-stock is of course Tesla. This week Hyundai Motors seems to have been given a rerating as the market is now focusing more on its advances in new tech than its ability to build automobiles. Analyst Julie Boote discusses the value AI can create for the large automakers. While success will depend on the smooth integration of software / AI into automakers’ fleets, there is also the question of whether robotics can generate a s...
Development Investment Construction Jsc: 2 directors
Two Directors at Development Investment Construction Jsc sold 2,350,400 shares at 0.000VND. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Dadelo SA: 1 director
A director at Dadelo SA bought 6,456 shares at 66.261PLN and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
AirAsia X Berhad: 1 director
A director at AirAsia X Berhad sold 17,000,000 shares at 1.650MYR and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
M S Hidravlik AD: 1 director
A director at M S Hidravlik AD sold 1,000 shares at 5.000EUR and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date a...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the “2025 Annual Meeting”) on March 23, 2026 at 10:00 a.m. Eastern Time, in virtual-only format at , and any adjournments or postponements thereof. The Company's Board of Directors (the “Board”) also set a record date of February 12, 2026 entitling stockholders of record as of such date...
- Bert Colijn
BrainAurora Medical Technology Ltd: 1 director
A director at BrainAurora Medical Technology Ltd sold 8,000,000 shares at 6.740HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Proposals by Huhtamäki Oyj’s Shareholders’ Nomination Board to the Ann...
Proposals by Huhtamäki Oyj’s Shareholders’ Nomination Board to the Annual General Meeting of Shareholders HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 16.1.2026 AT 14:00 EET Proposals by Huhtamäki Oyj’s Shareholders’ Nomination Board to the Annual General Meeting of Shareholders Huhtamäki Oyj’s (the "Company") Shareholders’ Nomination Board submits the following proposals to the 2026 Annual General Meeting (the "AGM") which is planned to be held on Wednesday, April 29, 2026. The proposals will also be included in the notice to convene the AGM, which will be published at a later date. Compositio...
Huhtamäki Oyj:n osakkeenomistajien nimitystoimikunnan ehdotukset varsi...
Huhtamäki Oyj:n osakkeenomistajien nimitystoimikunnan ehdotukset varsinaiselle yhtiökokoukselle HUHTAMÄKI OYJ PÖRSSITIEDOTE 16.1.2026 KLO 14.00 Huhtamäki Oyj:n osakkeenomistajien nimitystoimikunnan ehdotukset varsinaiselle yhtiökokoukselle Huhtamäki Oyj:n osakkeenomistajien nimitystoimikunta esittää seuraavat ehdotukset vuoden 2026 varsinaiselle yhtiökokoukselle, joka on suunniteltu pidettäväksi keskiviikkona 29.4.2026. Ehdotukset tullaan sisällyttämään myös yhtiökokouskutsuun, joka julkistetaan myöhempänä ajankohtana. Hallituksen kokoonpano Osakkeenomistajien nimitystoimikunta ehdotta...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) WATERTOWN, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 13,900 shares of EyePoint...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.